Myriad Genetics (MYGN) reported $213.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.2%. EPS of $0.06 for the same period compares to -$0.03 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $209.82 million, representing a surprise of +1.66%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being $0.02.While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...